Scholarlink

<p>Neoadjuvant chemotherapy (NACT) in breast cancer has been used for decades in patients with inflammatory, locally advanced, or inoperable breast cancer to achieve or facilitate operability and increase both local and systemic control. This retrospective analysis aims to identify risk factors for failing to achieve a pathological complete response (pCR). Additionally, the study examines factors predicting survival outcomes in breast cancer patients who received NACT. Among 224 patients who underwent NACT between 2010 and 2020, 65 patients achieved pCR. The hormone receptor (HR) status, HER2 amplification, and biological subtype of breast cancer significantly affected the patient’s ability to achieve a pCR. Stage of the disease, molecular type, and histological type of breast cancer were significant predictors of overall survival in breast cancer patients who achieved pCR after NACT. Notably, early-stage disease, the luminal subtype of breast cancer, and invasive mammary carcinoma of no special type (NST) were associated with a favorable prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Factors Predicting Pathological Complete Response and Survival Outcomes in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

  • 期刊论文

  • 发表日期：

    2025年2月11日

查看全文
  • Dhanya Mary Louis,
  • Merin Mathew,
  • Georg Gutjahr,
  • Narmada MP,
  • Lakshmi Malavika Nair,
  • Renjitha Bhaskaran,
  • Vijaykumar Dehannathparambil Kottarathil

摘要

Neoadjuvant chemotherapy (NACT) in breast cancer has been used for decades in patients with inflammatory, locally advanced, or inoperable breast cancer to achieve or facilitate operability and increase both local and systemic control. This retrospective analysis aims to identify risk factors for failing to achieve a pathological complete response (pCR). Additionally, the study examines factors predicting survival outcomes in breast cancer patients who received NACT. Among 224 patients who underwent NACT between 2010 and 2020, 65 patients achieved pCR. The hormone receptor (HR) status, HER2 amplification, and biological subtype of breast cancer significantly affected the patient’s ability to achieve a pCR. Stage of the disease, molecular type, and histological type of breast cancer were significant predictors of overall survival in breast cancer patients who achieved pCR after NACT. Notably, early-stage disease, the luminal subtype of breast cancer, and invasive mammary carcinoma of no special type (NST) were associated with a favorable prognosis.